Specific Receptor Sites for Chemotactic Peptides on Human Polymorphonuclear Leukocytes
Overview
Authors
Affiliations
Synthetic N-formylmethionyl peptides are chemotactic attractants for human polymorphonuclear leukocytes. The well-defined structure-activity relationship of these peptides in eliciting a chemotactic response suggests that the interaction of the peptides with a specific cellular binding site may initiate chemotaxis. By using tritiated N-formylmethionyl-leucyl-phenylalanine (fMet-Leu-[3H]Phe), a potent chemotactic peptide with high specific radioactivity, we have directly identified binding sites on human polymorphonuclear leukocytes. Binding of fMet-Leu-[3H]Phe to polymorphonuclear leukocytes is rapid (t1/2 less than 2 min) and reversible. The equilibrium dissociation constant (KD) for the interaction of fMet-Leu-[3H-A1Phe with the binding site is 12-14 nM at 37 degrees. The number of binding sites is approximately 2000 per cell. The specificity of the binding sites for a series of N-formylmethionyl peptides exactly reflects the specificity of the chemotactic response to the peptides in that they compete for the binding sites and initiate chemotaxis with the same order of potency (fMet-Leu-Phe greater than fMet-Met-Met greater than fMet-Phe greater than fMet-Leu greater than fMet),fPhe-Met is a competitive antagonist of the chemotactic activity of N-formylmethionyl peptides and has a calculated KD of 6x10-5 M. FPhe-Met also half-maximally inhibits binding of fMet-Leu[3H]Phe binding was the highest in polymorphonuclear leukocytes. No binding of fMet-Leu-[3H]Phe to human erythrocytes could be detected. These data indicate that fMet-Leu-[3H]Phe can be used to identify binding sites for chemotactic peptides on human polymorphonuclear leukocytes. It is likely that these binding sites initiate the specific response of motile cells to N-formylmethionyl peptides.
Formyl peptide receptors in bone research.
Lantieri M, Perdomo Trejo J, Le Q, Dighe A, Cui Q, Yang X Connect Tissue Res. 2022; 64(3):229-237.
PMID: 36440821 PMC: 10164673. DOI: 10.1080/03008207.2022.2149397.
Qin C, Norling L, Vecchio E, Brennan E, May L, Wootten D Br J Pharmacol. 2022; 179(19):4617-4639.
PMID: 35797341 PMC: 9545948. DOI: 10.1111/bph.15919.
Screening of Neutrophil Activating Factors from a Metagenome Library of Sponge-Associated Bacteria.
Okamura Y, Takahashi H, Shiida A, Hirata Y, Takeyama H, Suzuki K Mar Drugs. 2021; 19(8).
PMID: 34436266 PMC: 8402132. DOI: 10.3390/md19080427.
Marutani T, Nishino K, Miyaji T, Kamada K, Ohura K, Kiso Y Int J Mol Sci. 2021; 22(8).
PMID: 33920954 PMC: 8071274. DOI: 10.3390/ijms22084084.
Neutrophil Signaling That Challenges Dogmata of G Protein-Coupled Receptor Regulated Functions.
Dahlgren C, Holdfeldt A, Lind S, Martensson J, Gabl M, Bjorkman L ACS Pharmacol Transl Sci. 2020; 3(2):203-220.
PMID: 32296763 PMC: 7155189. DOI: 10.1021/acsptsci.0c00004.